Current immunotherapies for renal cell carcinoma

Mhd Yaser Al-Marrawi, Sheldon L. Holder

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Immunotherapy, though not a new modality for cancer treatment, has enjoyed renewed vigor and interest over the last several years. Multiple new targets have been identified, and therapeutic agents are in varying stages of development, with some agents having obtained regulatory approval for administration in the clinic. Renal cell carcinoma is known to potentially respond favorably to immunotherapy, with a small subset of patients achieving durable responses to high dose interleukin-2 therapy. Consequently, renal cell carcinoma is one of the many tumor types in which the efficacy of new agents is being investigated. Here we examine the landscape of current immunotherapeutic options for renal cell carcinoma, including cytokine therapy, immune checkpoint blockade, hematopoietic stem cell transplant, and vaccine therapy. We review approved immune directed therapies as well as new agents undergoing clinical trials in renal cell carcinoma. Immunotherapy has been and remains a promising treatment modality in this tumor type. Hopefully the approval of newer agents will translate into more accessible and efficacious options for patients and oncologists.

Original languageEnglish (US)
Pages (from-to)252-263
Number of pages12
JournalCurrent Molecular Pharmacology
Volume9
Issue number3
DOIs
StatePublished - Aug 1 2016

Fingerprint

Renal Cell Carcinoma
Immunotherapy
Therapeutics
Active Immunotherapy
Neoplasms
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Interleukin-2
Clinical Trials
Cytokines
Transplants

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Pharmacology
  • Drug Discovery

Cite this

Al-Marrawi, Mhd Yaser ; Holder, Sheldon L. / Current immunotherapies for renal cell carcinoma. In: Current Molecular Pharmacology. 2016 ; Vol. 9, No. 3. pp. 252-263.
@article{229c0d21e1d4411bb7413e87a4fb2022,
title = "Current immunotherapies for renal cell carcinoma",
abstract = "Immunotherapy, though not a new modality for cancer treatment, has enjoyed renewed vigor and interest over the last several years. Multiple new targets have been identified, and therapeutic agents are in varying stages of development, with some agents having obtained regulatory approval for administration in the clinic. Renal cell carcinoma is known to potentially respond favorably to immunotherapy, with a small subset of patients achieving durable responses to high dose interleukin-2 therapy. Consequently, renal cell carcinoma is one of the many tumor types in which the efficacy of new agents is being investigated. Here we examine the landscape of current immunotherapeutic options for renal cell carcinoma, including cytokine therapy, immune checkpoint blockade, hematopoietic stem cell transplant, and vaccine therapy. We review approved immune directed therapies as well as new agents undergoing clinical trials in renal cell carcinoma. Immunotherapy has been and remains a promising treatment modality in this tumor type. Hopefully the approval of newer agents will translate into more accessible and efficacious options for patients and oncologists.",
author = "Al-Marrawi, {Mhd Yaser} and Holder, {Sheldon L.}",
year = "2016",
month = "8",
day = "1",
doi = "10.2174/1874467208666150716121116",
language = "English (US)",
volume = "9",
pages = "252--263",
journal = "Current Molecular Pharmacology",
issn = "1874-4702",
publisher = "Bentham Science Publishers",
number = "3",

}

Current immunotherapies for renal cell carcinoma. / Al-Marrawi, Mhd Yaser; Holder, Sheldon L.

In: Current Molecular Pharmacology, Vol. 9, No. 3, 01.08.2016, p. 252-263.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Current immunotherapies for renal cell carcinoma

AU - Al-Marrawi, Mhd Yaser

AU - Holder, Sheldon L.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Immunotherapy, though not a new modality for cancer treatment, has enjoyed renewed vigor and interest over the last several years. Multiple new targets have been identified, and therapeutic agents are in varying stages of development, with some agents having obtained regulatory approval for administration in the clinic. Renal cell carcinoma is known to potentially respond favorably to immunotherapy, with a small subset of patients achieving durable responses to high dose interleukin-2 therapy. Consequently, renal cell carcinoma is one of the many tumor types in which the efficacy of new agents is being investigated. Here we examine the landscape of current immunotherapeutic options for renal cell carcinoma, including cytokine therapy, immune checkpoint blockade, hematopoietic stem cell transplant, and vaccine therapy. We review approved immune directed therapies as well as new agents undergoing clinical trials in renal cell carcinoma. Immunotherapy has been and remains a promising treatment modality in this tumor type. Hopefully the approval of newer agents will translate into more accessible and efficacious options for patients and oncologists.

AB - Immunotherapy, though not a new modality for cancer treatment, has enjoyed renewed vigor and interest over the last several years. Multiple new targets have been identified, and therapeutic agents are in varying stages of development, with some agents having obtained regulatory approval for administration in the clinic. Renal cell carcinoma is known to potentially respond favorably to immunotherapy, with a small subset of patients achieving durable responses to high dose interleukin-2 therapy. Consequently, renal cell carcinoma is one of the many tumor types in which the efficacy of new agents is being investigated. Here we examine the landscape of current immunotherapeutic options for renal cell carcinoma, including cytokine therapy, immune checkpoint blockade, hematopoietic stem cell transplant, and vaccine therapy. We review approved immune directed therapies as well as new agents undergoing clinical trials in renal cell carcinoma. Immunotherapy has been and remains a promising treatment modality in this tumor type. Hopefully the approval of newer agents will translate into more accessible and efficacious options for patients and oncologists.

UR - http://www.scopus.com/inward/record.url?scp=84989219367&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989219367&partnerID=8YFLogxK

U2 - 10.2174/1874467208666150716121116

DO - 10.2174/1874467208666150716121116

M3 - Review article

C2 - 26177641

AN - SCOPUS:84989219367

VL - 9

SP - 252

EP - 263

JO - Current Molecular Pharmacology

JF - Current Molecular Pharmacology

SN - 1874-4702

IS - 3

ER -